BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38204967)

  • 1. Structural and molecular characterization of lopinavir and ivermectin as breast cancer resistance protein (BCRP/ABCG2) inhibitors.
    Dutra JP; Scheiffer G; Kronenberger T; Gomes LJC; Zanzarini I; Dos Santos KK; Tonduru AK; Poso A; Rego FGM; Picheth G; Valdameri G; Moure VR
    EXCLI J; 2023; 22():1155-1172. PubMed ID: 38204967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
    To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
    J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2).
    da Silva Zanzarini I; Henrique Kita D; Scheiffer G; Karoline Dos Santos K; de Paula Dutra J; Augusto Pastore M; Gomes de Moraes Rego F; Picheth G; Ambudkar SV; Pulvirenti L; Cardullo N; Rotuno Moure V; Muccilli V; Tringali C; Valdameri G
    Bioorg Chem; 2024 May; 146():107283. PubMed ID: 38513324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2).
    Zattoni IF; Kronenberger T; Kita DH; Guanaes LD; Guimarães MM; de Oliveira Prado L; Ziasch M; Vesga LC; Gomes de Moraes Rego F; Picheth G; Gonçalves MB; Noseda MD; Ducatti DRB; Poso A; Robey RW; Ambudkar SV; Moure VR; Gonçalves AG; Valdameri G
    Chem Biol Interact; 2022 Jan; 351():109718. PubMed ID: 34717915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
    Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
    Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2.
    Shafi T; Jabeen I
    Curr Cancer Drug Targets; 2017; 17(2):177-190. PubMed ID: 27585695
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Almansour NM; Abdelrahman AHM; Ismail Fagiree E; Ibrahim MAA
    J Biomol Struct Dyn; 2023; 41(16):7651-7664. PubMed ID: 36120948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development.
    Moinul M; Amin SA; Jha T; Gayen S
    Eur J Med Chem; 2022 Nov; 241():114628. PubMed ID: 35944339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Teng QX; Chen ZS; Kong D; Yang DH
    Front Pharmacol; 2018; 9():1236. PubMed ID: 30425643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
    Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
    Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
    Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
    Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The More the Better-Investigation of Polymethoxylated
    Stockmann P; Kuhnert L; Leinung W; Lakoma C; Scholz B; Paskas S; Mijatović S; Maksimović-Ivanić D; Honscha W; Hey-Hawkins E
    Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
    Wu CP; Murakami M; Wu YS; Lin CL; Li YQ; Huang YH; Hung TH; Ambudkar SV
    Biomed Pharmacother; 2022 May; 149():112922. PubMed ID: 36068781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles.
    Kita DH; Guragossian N; Zattoni IF; Moure VR; Rego FGM; Lusvarghi S; Moulenat T; Belhani B; Picheth G; Bouacida S; Bouaziz Z; Marminon C; Berredjem M; Jose J; Gonçalves MB; Ambudkar SV; Valdameri G; Le Borgne M
    Sci Rep; 2021 Jan; 11(1):1788. PubMed ID: 33469044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrahydroquinoline/4,5-Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2).
    Vesga LC; Kronenberger T; Tonduru AK; Kita DH; Zattoni IF; Bernal CC; Bohórquez ARR; Mendez-Sánchez SC; Ambudkar SV; Valdameri G; Poso A
    ChemMedChem; 2021 Sep; 16(17):2686-2694. PubMed ID: 33844464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.
    Bierman WF; Scheffer GL; Schoonderwoerd A; Jansen G; van Agtmael MA; Danner SA; Scheper RJ
    J Antimicrob Chemother; 2010 Aug; 65(8):1672-80. PubMed ID: 20551216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
    Krapf MK; Gallus J; Wiese M
    Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.